Study of PYC-001 eye injections for people with a type of inherited optic nerve disease
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a new medicine called PYC-001, given as an injection into the eye, for people with a specific genetic form of vision loss called autosomal dominant optic atrophy (ADOA). It aims to see if the treatment is safe and could help protect or improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of ADOA caused by a mutation in the OPA1 gene.
- You must be 18 years or older.
- Your vision in the study eye must be between 20/40 and 20/200 (moderate to severe vision loss).
- You must not have had any prior gene therapy or cell therapy for a retinal condition.
- You must be willing to use effective birth control if you or your partner can become pregnant.
- You must not have any other eye diseases or infections that could affect the study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with a genetic form of optic atrophy over time to understand how vision changes. It does not test a treatment but helps doctors learn more about the condition to improve care.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
This trial tests a gene therapy injection into the eye to improve vision in people with a specific type of inherited optic nerve disease called Leber’s hereditary optic neuropathy (LHON). It is aimed at people who have a particular genetic change and a history of vision loss lasting long enough to measure change, while checking for safety first.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
Hear when a new OPA1 Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.